fluorexon has been researched along with Cancer of Cervix in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fan, YB; Li, HX; Liu, YZ; Wang, Z; Yi, ZC; Yin, Y; Zhuang, FY | 1 |
Banerjee, R; Huilgol, N; Preetha, A | 1 |
2 other study(ies) available for fluorexon and Cancer of Cervix
Article | Year |
---|---|
Tellimagrandin I enhances gap junctional communication and attenuates the tumor phenotype of human cervical carcinoma HeLa cells in vitro.
Topics: Antineoplastic Agents; Connexin 43; Disease Progression; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Female; Fluoresceins; Gallic Acid; Gap Junctions; Gene Expression Regulation, Neoplastic; Glucosides; HeLa Cells; Humans; Hydrolyzable Tannins; In Vitro Techniques; Isoquinolines; Phenotype; Uterine Cervical Neoplasms | 2006 |
Effect of fluidizing agents on paclitaxel penetration in cervical cancerous monolayer membranes.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Membrane Permeability; Drug Combinations; Fatty Alcohols; Female; Fluoresceins; Fluorescent Dyes; Humans; In Vitro Techniques; Liposomes; Membrane Fluidity; Membranes, Artificial; Models, Biological; Paclitaxel; Phospholipids; Phosphorylcholine; Polyethylene Glycols; Surface-Active Agents; Uterine Cervical Neoplasms | 2007 |